• ̍̍ CSE: BRAX
  • ̍̍ OTC: BRAXF
  • ̍̍ FWB: 4960

COVID-19

October 21, 2021

Journal of the Royal Society of Medicine

Journal of the Royal Society of Medicine Publishes New COVID-19 Suicide Research Led by Braxia Scientific CEO Dr. Roger McIntyre Journal of the Royal Society of Medicine Publishes New COVID-19 Suicide Research Led by Braxia Scientific CEO Dr. Roger McIntyre Findings Underscore Company Core Objectives to Develop Ketamine Derivatives as Additional Measures to Further Reduce Suicidality TORONTO, ONTARIO October 21, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce the publication of a new study led by Braxia Scientific CEO Dr. Roger McIntyre in the Journal of the Royal Society of Medicine. The publication, entitled “Suicide reduction in Canada during the COVID-19 pandemic: lessons informing national prevention strategies for suicide reduction” was initiated to evaluate...

July 4, 2021

‘Loneliness pandemic’: Work from home during COVID-19 takes mental toll on Canadians

“Working from home for many people in our society is a risk for further alienation and feeling very lonely and distant,” said Dr. Roger McIntyre”